Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Retained Earnings (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Retained Earnings data on record, last reported at $3.2 million in Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.19% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, up 100.19%, while the annual FY2025 figure was $3.2 million, 100.19% up from the prior year.
  • Retained Earnings reached $3.2 million in Q4 2025 per RVMD's latest filing, up from -$2.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $3.2 million in Q4 2025 and bottomed at -$2.5 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$766.2 million, with a median of -$540.9 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: tumbled 810073.02% in 2022, then surged 100.19% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$452.6 million in 2021, then surged by 99.61% to -$1.8 million in 2022, then plummeted by 63816.18% to -$1.1 billion in 2023, then plummeted by 52.75% to -$1.7 billion in 2024, then soared by 100.19% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $3.2 million in Q4 2025, -$2.5 billion in Q3 2025, and $1.3 million in Q2 2025.